Want to see VDRM full AI Analyst Report?
VDRM Stock Chart & Stats
<$0.01
$0.00(0.00%)
At close: 4:00 PM EDT
<$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.02
Previous CloseN/A
Volume15.00
Average Volume (3M)581.10K
Market Cap
$123.37K
Enterprise Value$806.18K
Total Cash (Recent Filing)$1.49M
Total Debt (Recent Filing)$1.86M
Price to Earnings (P/E)115.0
Beta-2.97
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,233,713,100
10 Day Avg. Volume428,867
30 Day Avg. Volume581,103
Financial Highlights & Ratios
PEG Ratio-30.47
Price to Book (P/B)101.36
Price to Sales (P/S)20.79
P/FCF Ratio71.33K
Enterprise Value/Market Cap6.53
Enterprise Value/Revenue1.79
Enterprise Value/Gross Profit1.79
Enterprise Value/Ebitda-6.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent revenue growth indicates strong demand for ViaDerma's products and successful market penetration, supporting long-term business expansion.
Gross Profit MarginsHigh gross profit margins reflect efficient cost management and pricing power, enhancing ViaDerma's ability to generate profits from sales.
Improved Equity StandingPositive equity indicates improved financial health and stability, providing a stronger foundation for future growth and investment.
Bears Say
Declining Net Profit MarginsDeclining net profit margins suggest rising expenses or inefficiencies, which could impact ViaDerma's long-term profitability and financial health.
Lack Of Cash Flow DataThe absence of detailed cash flow data hinders the assessment of ViaDerma's cash generation ability, impacting evaluations of its financial sustainability and operational efficiency.
High LeverageHigh leverage increases financial risk and limits flexibility, potentially affecting ViaDerma's ability to invest in growth opportunities or weather economic downturns.
VDRM FAQ
What was ViaDerma’s price range in the past 12 months?
ViaDerma lowest stock price was <$0.01 and its highest was $0.02 in the past 12 months.
What is ViaDerma’s market cap?
ViaDerma’s market cap is $123.37K.
When is ViaDerma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ViaDerma’s earnings last quarter?
ViaDerma released its earnings results on Oct 03, 2024. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is ViaDerma overvalued?
According to Wall Street analysts ViaDerma’s price is currently Overvalued.
Does ViaDerma pay dividends?
ViaDerma does not currently pay dividends.
What is ViaDerma’s EPS estimate?
ViaDerma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ViaDerma have?
ViaDerma has 1,233,713,100 shares outstanding.
What happened to ViaDerma’s price movement after its last earnings report?
ViaDerma reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of ViaDerma?
Currently, no hedge funds are holding shares in VDRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ViaDerma
ViaDerma, Inc., a specialty pharmaceutical enterprise based in the United States, focuses on both the development and commercialization of pharmaceutical products. It also licenses its proprietary technology to other companies within the pharmaceutical sector, addressing various therapeutic areas. The company's primary offering is Vitastem, a topical antibiotic containing tetracycline, effective for treating a broad spectrum of ailments such as cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. Beyond its established products, ViaDerma is dedicated to expanding its pipeline, with ongoing development in fields including advanced topical antibiotics, antifungal treatments for toenails, diabetic amputation recovery, general acne, psoriasis, eczema, burn care, anti-aging and wrinkle-reducing formulations, medical cannabis applications, male pattern baldness, skin cancer, erectile dysfunction, and pain management. Established in 2007, the company operated as Décor Products International, Inc. until its renaming to ViaDerma, Inc. in May 2014. Its corporate operations are directed from Marina Del Rey, California.
Technical Analysis
China Pharma Holdings
―
Sonoma Pharmaceuticals
―
―
PainReform
―
Shuttle Pharmaceuticals Holdings, Inc.
―